With mixed emotions, I have made the decision to leave Global Center for Medical Innovation (GCMI) and to start an exciting new chapter in my career. I am leaving GCMI to join the University City Science Center in Philadelphia as President and CEO effective October 1.


The decision to leave GCMI has not been an easy one for me. I have thoroughly enjoyed the time over the last 9 years working with our team to build the organization from a grant application to a truly comprehensive medical technology innovation and commercialization center.  It has been an honor and a privilege to work with all of you as colleagues and clients / sponsors. I am proud of what we have accomplished together and look forward to watching GCMI continue to grow, evolve and serve the medtech ecosystem in the coming years.


Over the next few weeks, I will be working with the GCMI Board and my leadership team on an interim CEO, as well as a search for the new CEO. As those conversations evolve, we will release necessary information to our sponsors, clients and colleagues.


There are no words that can express how sincerely grateful I am for the privilege of knowing, collaborating with and working with all of you. However, I know I am leaving GCMI in the best position to continue fulfilling its mission of accelerating the development, testing, training and commercialization of innovative medical products.


Though I will be leaving the Southeast region to pursue this opportunity, we are as an industry connected globally and I am certain our paths will cross again. And though I am leaving, the skilled leadership team at GCMI will remain in place and available for your next innovative concept needing to come to life, with a commitment to quality and service, as always.


Please reach out to me should you have any questions over the next month. I can be reached at GCMI until September 30, 2020 and after that time, do not hesitate to reach out via LinkedIn.


Thank you for your support over the years in making GCMI the Southeast’s organization to accelerate MedTech Innovation.